EU DMF readiness
US DMF readiness
💉 Available also
in injectable form
Alendronate sodium is indicated for the treatment of post-menopausal osteoporosis; reduces the risk of vertebral and hip fractures. Alendronate sodium is indicated for the treatment of osteoporosis in men at increased risk of fracture. A reduction in the incidence of vertebral, but not of non-vertebral fractures has been demonstrated. Alendronate sodium is used in the prophylaxis of glucocorticoid-induced osteoporosis.
It is formulated as tablets for oral route of administration.
Mechanism of action:
Alendronate sodium is a bisphosphonate that inhibits osteoclastic bone resorption with no direct effect on bone formation. Preclinical studies have shown preferential localization of alendronate sodium to sites of active resorption. Activity of osteoclasts is inhibited, but recruitment or attachment of osteoclasts is not affected. The bone formed during treatment with alendronate sodium is of normal quality.
Products protected by valid patents are not offered for commercial sale in countries where the sale of such products constitutes patent infringement but are offered solely for uses reasonably related to the development and submission of information under a law regulating the manufacture, use or sale of drugs. It is within the buyer’s responsibility and liability to check the patent situation of the product in the imported market(s).